Follicular dendritic cells (FDCs) are cells of the immune system found in primary and secondary lymph follicles of the B cell areas of the lymphoid tissue.[1] These cells were first described in 1965 and were attributed to the group of dendritic cells (DCs) due to extensive “dendritic” processes on their surface. Unlike lymphoid and myeloid DCs, follicular DCs are not derived from the bone-marrow hematopoetic stem cell, but are of mesenchymal origin.[2]
|
Contents
- 1 Location and molecular markers
- 2 Development
- 3 Functions
- 3.1 Organizing lymphoid microarchitecture.
- 3.2 Antigens capturing, memory B-cells support
- 3.3 Trash removal
- 3.4 Preventing autoimmunity
- 4 Interaction with B-cells
- 5 New Development
- 6 Diseases
- 7 See also
- 8 References
|
Location and molecular markers[edit]
Follicular DCs are a non-migratory population found in primary and secondary follicles of the B cell areas of lymph nodes, spleen, and mucosa-associated lymphoid tissue (MALT). They form a stable network due to intercellular connections between FDCs processes and intimate interaction with follicular B cells.[3][4] Follicular DCs network typically forms the center of the follicle and does not extend from the follicle to the interfollicular regions or T- cell zone. Supposedly, this separation from the sites of earliest antigen processing and capture provide a protected environment in which opsonized antigens can be displayed for a long time without being proteolyzed or removed by phagocytic cells. Follicular DCs have high expression of complement receptors CR1 and CR2 (CD 35 and CD 21 respectively) and Fc-receptor FcγRIIb (CD32). Further FDCs specific molecular markers are FDC-M1, FDC-M2 and C4.[5] Unlike other DCs and macrophages, FDCs lack MHC class II antigen molecules and express few pattern-recognition receptors, so they have little ability to capture non-opsonized antigens.[6]
Development[edit]
Follicular DCs develop from putative mesenchymal precursors.[7] Severe combined immunodeficiency (SCID) mice models demonstrate that these precursors may be transmitted to recipients with bone marrow allotransplants, in which case both donors' and recipients' FDCs networks may later be found in recipients' lymphoid compartments.[8] Interaction between FDCs precursors and lymphoid cells mediated by TNF-a and lymphotoxin (LT) is crucial for normal FDCs development and maintenance. TNF-a binds on the TNF-RI receptor, while LT interacts with LTβ-receptor expressed on FDC precursors. In mice lacking B cells, or with blocked TNF-a and lymphotoxin (LT) production, cells with FDC phenotype are missing.[9][10]
Functions[edit]
Organizing lymphoid microarchitecture.[edit]
In normal lymphoid tissue recirculating resting B cells migrate through the FDC networks, whereas antigen-activated B cells are intercepted and undergo clonal expansion within the FDC networks, generating germinal centers (GC). FDCs are among main producers of the chemokine CXCL13 which attracts and organises lymphoid cells.[11]
Antigens capturing, memory B-cells support[edit]
Follicular DCs receptors CR1, CR2 and FcγRIIb trap antigen opsonized by complement or antibodies. To become selected as a future memory cell, GC B cells must bind the antigen presented on FDCs, otherwise they enter apoptosis.
Trash removal[edit]
By secreting the bridging factor Mfge8, which crosslinks apoptotic cells and phagocytes, FDCs promote selective debris removal from the GC.[12][13]
Preventing autoimmunity[edit]
Factor Mfge produced in lymphoid tissues mainly by FDCs is known to enhance engulfment of apoptotic cells. Deficit of this factor in mice leads to a state resembling systemic lupus erythematosus (SLE). Furthermore, mice lacking LT or LT receptors, which are devoid of FDC, develop generalized lymphocytic infiltrates, which are suggestive of autoimmunity. These findings suggest that FDC possibly protect organism against autoimmunity by the removal of potentially self-reactive debris from GC.[14]
Interaction with B-cells[edit]
To generate the follicular structures, FDCs need to be stimulated by lymphotoxin, a mediator produced by B cells. Also, noncognate B cells play a significant role as an antigen transporter to FDCs. They capture immune complexes in CR1/2-dependent way either directly from the blood or from macrophages, and putate to the lymphoid tissue, where they upload FDCs with opsonized antigen. FDCs, in turn, attract B cells with chemoattractant CXCL13. B cells lacking CXCR5, the receptor for CXCL13, still enter the white pulp, but are mislocalized and disorganized. The stimulation of CXCR5 on B cells upregulates LT production, which leads to FDCs activation and stimulates further CXCL13 secretion, thus generating a positive feed-forward loop. This results in the formation of GC, where antigen-activated B cells are trapped to undergo somatic mutation, positive and negative selection, isotype switching and differentiation into high-affinity plasma cells and memory B cells. The adhesion between FDCs and B cells is mediated by ICAM-1 (CD54)-LFA-1(CD11a) and VCAM-VLA-4 molecules.[15] Activated B-cells with low affinity to antigen captured on FDCs surface as well as autoreactive B-cells undergo apoptosis, whereas B cells bound to FDCs through the antigen complex, survive due to apoptosis blockage caused by interaction with FDCs.
New Development[edit]
Research by Kristin Denzer and associates has shown that though the FDCs do not have MHC II attached to their membranes directly, microvesicles attached to their membranes contain MHC II molecules. The size and marker profile of these microvesicles resemble those of exosomes. They have been shown to activate Th cells in vitro, but in vivo function is not confirmed.
Diseases[edit]
Rare primary FDC-tumors have been described. These sarcomas often involve lymphoid tissues, but in a number of cases the tumor has been found in the liver, bile duct, pancreas, thyroid, nasopharynx, palatum, submucosa of the stomach or the duodenum. In a number of chronic inflammatory conditions, cells producing CXCL13 chemokine and carrying such FDCs markers as VCAM-1 and CD21, have been observed at quite unexpected sites, including synovial tissue of patients with rheumatoid arthritis (RA), salivary glands of patients with Sjögren’s syndrome, and the skin of patients with pseudo B cells lymphoma.[16] Follicular dendritic cells participate in HIV-1 infection development both, by providing a haven for HIV-1[17][18] and by stimulating HIV-1 replication in adjacent infected monocytic cells via a juxtacrine signaling mechanism.[19] There are also some evidences, that FDCs may promote prion replication and neuroinvasion in neuroinvasive scrapie.[20]
See also[edit]
- Follicular Dendritic Cells at the US National Library of Medicine Medical Subject Headings (MeSH)
- Follicular Dendritic Cell (FDC) web site
References[edit]
- ^ Liu Y, Grouard G, de Bouteiller O, Banchereau J (1996). "Follicular dendritic cells and germinal centers". Int Rev Cytol. International Review of Cytology 166: 139–79. doi:10.1016/S0074-7696(08)62508-5. ISBN 978-0-12-364570-8. PMID 8881775.
- ^ Banchereau J, Steinman RM (1998). "Dendritic cells and the control of immunity". Nature 392: 245–52. doi:10.1038/32588. PMID 9521319. van Nierop K, de Groot C (2002). "Human follicular dendritic cells: function, origin and development". Semin Immunol 14 (4): 251–7. doi:10.1016/S1044-5323(02)00057-X. PMID 12163300.
- ^ Male D, Brostoff J, Roth D, Roitt I (2007). Immunology, 7th edition. ISBN 978-0-323-03399-2.
- ^ Banchereau J, Steinman RM (1998). "Dendritic cells and the control of immunity". Nature 392: 245–52. doi:10.1038/32588. PMID 9521319.
- ^ van Nierop K, de Groot C (2002). "Human follicular dendritic cells: function, origin and development". Semin Immunol 14 (4): 251–7. doi:10.1016/S1044-5323(02)00057-X. PMID 12163300.
- ^ Male D, Brostoff J, Roth D, Roitt I (2007). Immunology, 7th edition. ISBN 978-0-323-03399-2.
- ^ van Nierop K, de Groot C (2002). "Human follicular dendritic cells: function, origin and development". Semin Immunol 14 (4): 251–7. doi:10.1016/S1044-5323(02)00057-X. PMID 12163300.
- ^ Kapasi ZF, Qin D, Kerr WG, Kosco-Vilbois MH, Shultz LD, Tew JG, Szakal AK (1998). "Follicular dendritic cell (FDC) precursors in primary lymphoid tissues". The Journal of Immunology 160 (3): 1078–84. PMID 9570519.
- ^ Wang Y, Wang J, Sun Y, Wu Q, Fu YX (2001). "Complementary effects of TNF and lymphotoxin on the formation of germinal center and follicular dendritic cells". J Immunol 166 (1): 330–7. PMID 11123309.
- ^ Ettinger R, Mebius R, Browning JL, Michie SA, van Tuijl S, Kraal G, van Ewijk W, McDevitt HO (1998). "Effects of tumor necrosis factor and lymphotoxin on peripheral lymphoid tissue development". Int Immunol 10 (6): 727–41. PMID 9678753.
- ^ Cyster JG (2010). "B cell follicles and antigen encounters of the third kind.". Nat Immunol. 11 (11): 989–96. doi:10.1038/ni.1946. PMID 20959804.
- ^ Aguzzi A, Krautler NJ. (2010). "Characterizing follicular dendritic cells: A progress report.". Eur J Immunol. 40 (8): 2134–8. doi:10.1002/eji.201040765. PMID 20853499.
- ^ Kranich J, Krautler NJ, Heinen E, Polymenidou M, Bridel C, Schildknecht A, Huber C, Kosco-Vilbois MH, Zinkernagel R, Miele G, Aguzzi A. (2008). "Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8.". J Exp Med. 205 (6). doi:10.1084/jem.20071019. PMID 18490487.
- ^ Aguzzi A, Krautler NJ. (2010). "Characterizing follicular dendritic cells: A progress report.". Eur J Immunol. 40 (8): 2134–8. doi:10.1002/eji.201040765. PMID 20853499.
- ^ van Nierop K, de Groot C (2002). "Human follicular dendritic cells: function, origin and development". Semin Immunol 14 (4): 251–7. doi:10.1016/S1044-5323(02)00057-X. PMID 12163300.
- ^ van Nierop K, de Groot C (2002). "Human follicular dendritic cells: function, origin and development". Semin Immunol 14 (4): 251–7. doi:10.1016/S1044-5323(02)00057-X. PMID 12163300.
- ^ Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, Henry K, Zhang ZQ, Mills R, McDade H, Schuwirth CM, Goudsmit J, Danner SA, Haase AT (1997). "Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection". Science 276 (5314): 960–4. doi:10.1126/science.276.5314.960. PMID 9139661.
- ^ Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS (1993). "HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease". Nature 362 (6418): 355–8. doi:10.1038/362355a0. PMID 8455722.
- ^ Ohba K, Ryo A, Dewan MZ, Nishi M, Naito T, Qi X, Inagaki Y, Nagashima Y, Tanaka Y, Okamoto T, Terashima K, Yamamoto N (2009). "Follicular dendritic cells activate HIV-1 replication in monocytes/macrophages through a juxtacrine mechanism mediated by P-selectin glycoprotein ligand 1". J Immunol 183: 524–32. doi:10.4049/jimmunol.0900371. PMID 19542463.
- ^ Montrasio F, Frigg R, Glatzel M, Klein MA, Mackay F, Aguzzi A, Weissmann C (2000). "Impaired prion replication in spleens of mice lacking functional follicular dendritic cells". Science 288 (5469): 1257–9. doi:10.1126/science.288.5469.1257. PMID 10818004.
|
Myeloid lineage - Blood (WBC and RBC)
|
|
Cellular/
HSCs |
|
Myeloid/
CFU-GEMM
|
|
CFU-GM
|
|
CFU-G:
Granulocytes
|
Band cell · Neutrophil
|
|
|
|
|
Macrophages
|
Histiocytes · Kupffer cells · Alveolar macrophage · Microglia · Osteoclasts · Epithelioid cells · giant cells (Langhans giant cells, Foreign-body giant cell, Touton giant cells)
|
|
|
CFU-DL
|
Dendritic cells · Langerhans cell
|
|
|
|
Common
|
Myelomonocyte
|
|
|
|
CFU-Baso
|
Granulocytes (Basophil)
|
|
|
CFU-Eos
|
Granulocytes (Eosinophil)
|
|
|
MEP
|
|
CFU-Meg
|
Megakaryoblast (* primitive Kacheshmarova's cell) · Megakaryocyte (Kacheshmarova's cell) · Platelets
|
|
|
CFU-E
|
Reticulocyte · Normoblast
|
|
|
|
CFU-Mast
|
Mast cell precursors
|
|
|
|
| Noncellular |
Plasma
|
|
|
|
cell/phys (coag, heme, immu, gran), csfs
|
rbmg/mogr/tumr/hist, sysi/epon, btst
|
drug (B1/2/3+5+6), btst, trns
|
|
|
|
